Matthew Kurian, Assistant professor of medicine at the University of Kentucky College of Medicine, shared a post on LinkedIn:
“Practice-Changing Data in Metastatic TNBC?
The press release from ASCENT-04 is in—and it may reshape frontline therapy for metastatic triple-negative breast cancer (mTNBC)!
Gilead’s sacituzumab govitecan (Trodelvy) + pembrolizumab (Keytruda) significantly improved progression-free survival vs chemo + pembrolizumab in PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (mTNBC).
This is the first-ever antibody-drug conjugate (ADC) + immunotherapy (IO) combo to outperform chemo + IO in metastatic breast cancer.
Why it matters:
- KEYNOTE-355 established chemo + pembrolizumab in CPS ≥10 as the standard.
- Now, ASCENT-04 shows Trodelvy + Keytruda may be more effective in the same population.
- This could signal a paradigm shift: ADCs as frontline IO partners, not just later-line salvage agents.
The future of TNBC treatment may no longer rely on conventional chemo—this is a huge moment!